What Alprostadil Towa Treats: Main Uses and Benefits

Alprostadil therapy is centered on managing symptoms across two highly specialized, distinct clinical domains: assisting adult males to support functional capacity and providing supportive circulatory assistance in newborn infants with severe congenital heart conditions. The medication is commonly used for both of these primary therapeutic areas.

This medicine is considered relevant for use in conditions presenting with acute or disruptive symptom patterns, including the symptomatic management of erectile dysfunction (impotence) and as a palliative bridge for ductal-dependent congenital heart defects in neonates.

“The primary intent of therapy is to generally provide supportive relief during periods of heightened symptoms, whether they involve functional strain in adults or critical physiological imbalance in newborns.”

Symptomatic Relief for Erectile Dysfunction (ED)

This domain covers the management of impotence, or the chronic inability for adult males to achieve and maintain a penile erection sufficient for sexual intercourse. It is considered relevant for easing symptoms associated with physical causes such as poor blood vessel function (vasculogenic causes) or nerve issues (neurogenic causes), especially when groups of symptoms related to ED have been unsuccessful with first-line oral therapies. The key benefit is that it supports the achievement of adequate erectile function, offering a relevant option for symptomatic management that helps ease the functional and psychological strain associated with this condition.

Quick Fact: Support for Functional Strain The medicine is generally applied when symptoms create noticeable functional strain related to physiological causes, and may be part of symptomatic management during diagnostic procedures.

Palliative Support for Critical Neonatal Heart Conditions

This domain involves the acute use of the medication in the immediate postnatal period for newborn infants diagnosed with ductal-dependent congenital heart defects (DDCHD). Alprostadil is applied in clinical settings that involve acute or unstable symptom patterns to manage symptoms associated with critical circulatory strain, such as pronounced lack of oxygen (hypoxemia) and cyanosis. This action assists with temporary circulatory stabilization, acting as a necessary palliative bridge that supports a state of physiological stability while the baby awaits definitive corrective or palliative cardiac procedures.

Regulatory References

1. NIH StatPearls overview

The use of Alprostadil Towa is defined by strict population eligibility rules outlined in official regulatory documents for its two primary patient groups: Adult Males (for erectile dysfunction) and Newborn Infants (for ductal-dependent heart defects).

Eligibility Classification	Population Group
Allowed Use	Adult Males (ED) and Newborn Infants (DDCHD).
Contraindicated Use	Females; males with a known hypersensitivity to the drug; males with a penile implant.
Absolute Contraindication	Males with conditions predisposing to priapism (e.g., sickle cell anemia, leukemia, multiple myeloma).
Absolute Contraindication	Males with fibrotic penile conditions, including Peyronie’s disease, angulation, or cavernosal fibrosis.

Conditional Use & Restrictions

The medicine requires special caution or conditional use in specific populations as defined in the label. This includes patients with severe cardiovascular or cerebrovascular disease for whom sexual activity is deemed inadvisable. Caution is also advised for patients with severe renal or hepatic impairment due to potential changes in drug clearance, and for those on anticoagulant therapy due to increased risk of local bleeding. Use in infants is closely restricted to the neonatal period for palliative heart support, and safety is not established for non-neonatal children or adolescents.

The official regulatory interaction profile for alprostadil is based primarily on its inherent actions as a potent vasodilator and an inhibitor of platelet aggregation. Regulatory documents establish restrictions on co-administration to manage potential additive effects.

Pharmacodynamic Interactions and Restrictions

Co-administration with other intracavernosally injected vasoactive agents is not recommended in regulatory labels, as the systematic study of these combinations is lacking, and there is a heightened risk of prolonged erection and hypotension. Similarly, official guidelines caution against combining alprostadil with oral Phosphodiesterase Type-5 (PDE5) inhibitors (such as sildenafil or tadalafil), citing a potential additive increased cardiovascular risk.

Due to alprostadil’s effect on platelet function, patients taking anticoagulants (including warfarin or heparin) may have an increased propensity for injection site bleeding following administration.

Metabolic Interactions and Population Notes

The potential for pharmacokinetic drug-drug interactions (involving CYP enzymes or transporters) has not been formally studied or documented according to the prescribing information for many formulations. This constitutes a formal lack of data in the regulatory profile. In the specialized setting of neonatal care, no drug interactions have been reported between intravenous alprostadil and standard concurrent therapies, including antibiotics, cardiac glycosides, or vasopressors. Some regulatory documentation notes that dose reduction may be considered in patients with hepatic or renal insufficiency, though this is a caution based on the patient population rather than a specific documented drug-drug interaction finding.

Mechanism of Action: Activating Specific Prostaglandin Receptors

Alprostadil, a synthetic version of PGE1, initiates its action by acting as a full agonist on specific Prostaglandin E-type receptors, primarily the EP2 and EP4 subtypes. These receptors are specialized G-protein coupled receptors found on the smooth muscle cell membrane. This binding event serves as the molecular switch that turns on a major intracellular signaling cascade.

Pathway Effect: Regulating Smooth Muscle Tone via cAMP

The activation of EP2 and EP4 receptors leads to the immediate stimulation of the enzyme Adenylate Cyclase. This enzyme rapidly produces large amounts of the second messenger, cyclic Adenosine Monophosphate (cAMP), inside the cell. . Elevated cAMP levels then trigger the downstream Protein Kinase A (PKA) cascade, which ultimately inhibits the cellular machinery responsible for muscle contraction, resulting in a functional reduction of intracellular calcium and a state of smooth muscle relaxation.

Physiological Consequence: Local Vasodilation

The resulting relaxation of the smooth muscle, particularly within the walls of arteries and vascular structures, leads directly to local vasodilation (widening of blood vessels). This opening of the vasculature increases local blood flow. The effect is highly localized and short-lived because the molecule is designed to be rapidly metabolized by the enzyme 15-hydroxyprostaglandin dehydrogenase ( 15-PGDH), and the rapid metabolism contributes to confining its impact largely to the area of administration.

Alprostadil Towa is administered via distinct routes and dosing protocols depending on the clinical context. For the management of erectile dysfunction (ED), the medicine may be used as an intracavernosal injection or, in some regions, a topical cream applied to the urethral meatus. The injection protocol mandates that the first dose and subsequent dose adjustments (titration) must be administered in a supervised medical setting until the individual maintenance dose is established. This maintenance dose is limited to a maximum of 60 micrograms ( mu g) and is used on an intermittent basis, no more than three times per week, with a minimum interval of 24 hours between doses. The goal of titration is to find a dose that produces an erection lasting no longer than one hour.

The use of alprostadil for ductal-dependent congenital heart defects in neonates employs a specialized approach. This application requires the medicine to be delivered as a continuous intravenous or intra-arterial infusion. Dosing is determined strictly by the infant's body weight, typically beginning in the range of 0.05 to 0.1 mu g/kg/min. Once the desired circulatory effect is achieved, the infusion rate is gradually reduced to the lowest effective dose. Due to the acute and time-sensitive nature of this neonatal therapy, it is administered for the shortest duration necessary, serving as a palliative bridge until corrective procedures can be undertaken.

Recent Clinical Evidence

Recent research has focused on the efficacy and tolerability of alprostadil, the active compound in Alprostadil Towa, primarily as a second-line treatment for erectile dysfunction (ED). Alprostadil is a synthetic analogue of Prostaglandin E1, a naturally occurring substance that acts as a vasodilator. The agent has been evaluated in various formulations, including intracavernosal injection, intraurethral suppository, and topical cream.

---

Efficacy Data from Meta-Analyses

A systematic review and meta-analysis of multiple randomized controlled trials (RCTs) examined the effect of topical and intraurethral alprostadil compared to placebo in men with ED. These analyses, involving thousands of patients, explored the change in the International Index of Erectile Function (IIEF) score.

• Topical Formulation: Studies suggested a statistically significant difference in IIEF scores compared to placebo, although the magnitude of the score increase was noted as generally modest in some trials.
• Intraurethral Formulation: Research also indicated a statistically significant improvement in ED symptoms with the intraurethral pellet compared to placebo.

It is important to note that the strength of conclusions from these meta-analyses is sometimes limited by variability in study designs and the methodological quality of the included studies.

---

Safety and Tolerability

Clinical trials consistently report that the most frequently observed adverse events associated with alprostadil administration are generally localized, mild to moderate in severity, and transient. Common localized effects include penile pain and erythema (redness) at the site of administration. Serious adverse events, such as prolonged erection (priapism) or penile fibrosis, are known risks associated with the treatment method and require clinical monitoring.

Common questions about Alprostadil Towa (FAQ)

Q: How quickly does Alprostadil Towa start working?

A: Clinical data indicates that the expected onset of effect for the injection formulation is typically within 5 to 20 minutes after administration. For other local formulations, such as topical or intraurethral products, the onset may be slightly longer, generally occurring within 5 to 30 minutes. This information is based on official prescribing documents.

Q: How long do the effects of Alprostadil Towa typically last?

A: Regulatory documents state that the dosage should be set to achieve an erection lasting no longer than one hour. The actual duration of the effect is generally described as being short-lived, dose-dependent, and highly variable by individual. This limitation is described in regulatory documents as a measure to reduce the risk of a prolonged erection (priapism).

Q: What should I know about pain after using Alprostadil Towa?

A: Pain in the penis is classified in regulatory documentation as a very common adverse reaction associated with the medicine. Official safety data indicates that in the majority of cases, this pain has been assessed as mild or moderate in severity and is usually transient.

Q: What is the difference between Alprostadil Towa and other oral ED treatments?

A: The key difference is the method of action and administration. Unlike oral treatments, which act systemically (throughout the body), Alprostadil is administered locally (e.g., via injection or cream) as a potent vasodilator. This means its primary action of relaxing smooth muscle and increasing blood flow is confined to the specific area of administration.

Q: Is Alprostadil Towa a long-term treatment or short-term?

A: For erectile dysfunction, the medicine is used on an intermittent (as-needed) basis, and medical literature describes it as a safe option for supervised long-term use for the condition. However, for its specialized use in newborn infants with heart defects, it is a short-term therapy used as a temporary 'bridge' until corrective procedures can be performed.

Q: Does Alprostadil Towa affect fertility?

A: Official documentation indicates that formal fertility studies on the active ingredient have not been performed in human males. For this reason, official labels indicate that when the female partner is of childbearing potential or is pregnant, the use of a barrier method, such as a condom, is specified to avoid systemic exposure to the drug.

Q: What do clinical trials suggest about the onset of action?

A: Data from clinical trials suggests that the onset of the effect for the intracavernosal injection generally occurs within 5 to 20 minutes. This information confirms the rapid action of the medicine when administered directly.

Q: Does Alprostadil Towa contain latex?

A: Regulatory documents list the chemical ingredients (excipients) but may not always detail the materials used in the injection packaging or device components. The specific product information provided by the manufacturer contains the definitive details regarding the presence of latex.

Q: Is it normal to feel a warming sensation after use?

A: While the most common localized effects listed are pain and erythema (redness), some patient safety reports have included a sensation of penile warmth or a burning feeling. This has been noted especially with the topical formulations.

Q: Is Alprostadil Towa the same as other forms of Alprostadil?

A: Alprostadil Towa contains the same active ingredient, alprostadil, which is the synthetic form of Prostaglandin E1. However, it is one of many brands and formulations (injection, cream, or suppository) available, which primarily differ in the inactive ingredients (excipients), specific concentrations, and the administration method.

Q: Can Alprostadil Towa cause changes in blood pressure?

A: As a potent vasodilator, systemic effects are possible, though localized use is intended. Official adverse reaction data lists both hypotension (low blood pressure) and syncope (fainting) as uncommon side effects. Hypertension (high blood pressure) has also been reported in safety data for some formulations.

Q: Are there any specific foods or drinks that interact with Alprostadil Towa?

A: Formal pharmacokinetic or pharmacodynamic interaction studies of the medicine with specific foods or beverages have generally not been performed or documented in official regulatory labels. Warnings provided in prescribing information are primarily focused on interactions with other prescription medications.

Q: Why is Alprostadil Towa only available by prescription?

A: The medicine is prescription-only due to the specialized nature of its use. Initial administration and any dose adjustments (titration) are required to be performed in a supervised medical setting. This is necessary to ensure the correct dose is achieved and to manage the risk of serious side effects like prolonged erection (priapism).

Q: Does Alprostadil Towa contain any known allergens?

A: The active ingredient is not generally considered a common allergen, but regulatory information lists excipients (inactive ingredients) in the formulation, such as lactose or benzyl alcohol, that could be potential allergens. The medicine is contraindicated (should not be used) in individuals with a known hypersensitivity to the drug.

Q: Is Alprostadil Towa a controlled substance?

A: Based on regulatory scheduling classifications (such as those applied to drugs with abuse potential by government bodies like the US DEA), the active ingredient alprostadil is not classified as a controlled substance.

Q: Are there any known interactions with herbal supplements or vitamins?

A: Official prescribing information generally focuses on interactions with prescription medicines, specifically anticoagulants (blood thinners) and other vasoactive agents. Regulatory documents typically do not provide detailed information regarding interactions with herbal supplements or vitamins.

Q: Is Alprostadil Towa used for any other conditions besides the main indication?

A: Yes, beyond treating erectile dysfunction and temporarily maintaining the ductus arteriosus in neonates, the medicine has been approved in some international jurisdictions for conditions related to peripheral arterial insufficiency, such as chronic arterial obstruction.

Q: Can Alprostadil Towa be used if I have low blood pressure?

A: Regulatory documents advise that the medicine should be administered with caution in patients who have pre-existing hypotension (low blood pressure). This is due to the potential for the medicine to increase blood levels of the active ingredient and risk further blood pressure lowering.

Q: What specific laboratory tests might be needed while using Alprostadil Towa?

A: For adult use, regulatory documents mandate regular follow-up to detect early signs of localized safety concerns, such as penile fibrosis. For the specialized use in neonates, continuous monitoring of arterial pressure and respiratory status is a requirement.

Q: What are the restrictions on alcohol consumption when using Alprostadil Towa?

A: Formal interaction studies with alcohol are generally not available in official prescribing information. Regulatory documents do not contain specific restrictions on alcohol or tobacco use; however, information on these specific interactions is generally not available in official labeling.

Q: How do I know if I'm a suitable candidate for Alprostadil Towa?

A: Official eligibility is determined by the absence of specific contraindications listed in regulatory documents. These contraindications include pre-existing conditions that predispose to prolonged erection (priapism), anatomical penile deformation (e.g., Peyronie's disease), and severe pre-existing cardiovascular disease that makes sexual activity inadvisable.

Q: Are there restrictions on physical activity after using the medicine?

A: While general physical activity is not typically restricted, patients are cautioned that activities requiring alertness, such as driving or operating heavy equipment, should be considered with care, as potential adverse reactions like hypotension (dizziness) or syncope (fainting) have been reported following administration.

Q: How does the medicine change circulation?

A: The medicine is a potent vasodilator that locally changes circulation by relaxing smooth muscle in the vessel walls. This action causes the blood vessels to widen, which results in a significant increase in local blood flow in the area where the medicine is administered.

Q: What is the difference between Alprostadil Towa and the compound Prostaglandin E1?

A: The active ingredient, alprostadil, is a synthetic analogue of the naturally occurring substance Prostaglandin E1 ( PGE1). Official documents describe it as being chemically identical to PGE1 but manufactured for use as a medicine.

Q: What are the general guidelines for use conditions, not instructions?

A: General use conditions require the initial dose and all adjustments (titration) to be performed in a supervised medical setting. Use is strictly limited to no more than three times per week and no more than once in a 24-hour period.

Q: Are there any known long-term complications described in official sources?

A: Known long-term risks documented in official sources for adult males include the development of penile fibrosis or severe penile angulation. For specialized use in neonates, prolonged treatment has been associated with changes such as cortical proliferation of the long bones.

Q: Is Alprostadil Towa known to cause any skin reactions?

A: Yes, localized skin reactions at the site of administration are known to occur. Adverse reaction data lists erythema (redness) and ecchymosis (bruising) as common effects, with less frequent reports of events like rash and pruritus (itching).

Q: What happens if I miss a scheduled time to use Alprostadil Towa?

A: Since the medicine is for on-demand intermittent use for erectile dysfunction and is not a daily scheduled therapy, the concept of a 'missed dose' does not apply. If a dose is not taken, the key safety rule is to ensure adherence to the minimum interval of 24 hours between doses.

Q: Is there a maximum number of times Alprostadil Towa can be used in a month?

A: Regulatory guidelines explicitly restrict use to no more than three times per week and no more than once per 24-hour period. Official documents emphasize adherence to this weekly maximum frequency, rather than stating a monthly total limit.

Q: Is there information about Alprostadil Towa's effectiveness for people with nerve damage?

A: Yes, the medicine is officially indicated for treating erectile dysfunction that stems from various causes, including those that are neurogenic (related to nerve function). Effectiveness has been evaluated in clinical studies that include men with neurogenic conditions.

How to Store and Dispose of Alprostadil Towa?

Strict storage conditions apply to Alprostadil Towa to ensure stability, as defined in official regulatory documents.

Product State	Storage Requirement
Unreconstituted Powder	Store in the refrigerator, between 2^circmathrmC and 8^circmathrmC (36^circmathrmF and 46^circmathrmF). Keep in the original container to protect from light.
Reconstituted Solution	Must be used within 24 hours when stored at or below 25^circmathrmC (77^circmathrmF). Do not refrigerate or freeze the mixed solution.

The vial is for single use only. It is critical to discard the vial and any remaining solution immediately after the required dose has been withdrawn. Dispose of the used syringe, needles, and any remaining solution according to local requirements for the disposal of medical waste.